591 related articles for article (PubMed ID: 29511902)
21. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
[TBL] [Abstract][Full Text] [Related]
22. [Immunotherapy is cancer treatment with a novel side-effect profile].
Kondrup M; Raunkilde L; Svane IM; Schmidt H; Bastholt L
Ugeskr Laeger; 2017 Oct; 179(40):. PubMed ID: 28992844
[TBL] [Abstract][Full Text] [Related]
23. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity.
Inno A; Metro G; Bironzo P; Grimaldi AM; Grego E; Di Nunno V; Picasso V; Massari F; Gori S
Tumori; 2017 Sep; 103(5):405-421. PubMed ID: 28497847
[TBL] [Abstract][Full Text] [Related]
24. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
25. [No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer].
Steenbruggen TG; van den Heuvel MM; Blank CU; van Dieren JM; Haanen JB; Kok M
Ned Tijdschr Geneeskd; 2016; 160():A9873. PubMed ID: 27438388
[TBL] [Abstract][Full Text] [Related]
26. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.
Makarious D; Horwood K; Coward JIG
Eur J Cancer; 2017 Sep; 82():128-136. PubMed ID: 28666240
[TBL] [Abstract][Full Text] [Related]
27. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint inhibitor therapy-induced hypophysitis ∼ a case series of Taiwanese patients.
Lin CH; Chen KH; Chen KY; Shih SR; Lu JY
J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):524-529. PubMed ID: 30104119
[TBL] [Abstract][Full Text] [Related]
29. Moving towards personalized treatments of immune-related adverse events.
Esfahani K; Elkrief A; Calabrese C; Lapointe R; Hudson M; Routy B; Miller WH; Calabrese L
Nat Rev Clin Oncol; 2020 Aug; 17(8):504-515. PubMed ID: 32246128
[TBL] [Abstract][Full Text] [Related]
30. Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy.
Brumbaugh AD; Narurkar R; Parikh K; Fanucchi M; Frishman WH
Cardiol Rev; 2019; 27(2):97-107. PubMed ID: 29912044
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.
Eigentler TK; Hassel JC; Berking C; Aberle J; Bachmann O; Grünwald V; Kähler KC; Loquai C; Reinmuth N; Steins M; Zimmer L; Sendl A; Gutzmer R
Cancer Treat Rev; 2016 Apr; 45():7-18. PubMed ID: 26922661
[TBL] [Abstract][Full Text] [Related]
32. Ocular and orbital side-effects of checkpoint inhibitors: a review article.
Antoun J; Titah C; Cochereau I
Curr Opin Oncol; 2016 Jul; 28(4):288-94. PubMed ID: 27136135
[TBL] [Abstract][Full Text] [Related]
33. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.
Tirumani SH; Ramaiya NH; Keraliya A; Bailey ND; Ott PA; Hodi FS; Nishino M
Cancer Immunol Res; 2015 Oct; 3(10):1185-92. PubMed ID: 26100356
[TBL] [Abstract][Full Text] [Related]
34. [Immune-related adverse events of immune checkpoint inhibitors].
Tadano H; Torigoe T
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):102-108. PubMed ID: 28603200
[TBL] [Abstract][Full Text] [Related]
35. [Toxicity of immune checkpoints inhibitors].
Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
[TBL] [Abstract][Full Text] [Related]
36. Hypophysitis: Nursing Management of Immune-Related Adverse Events
.
Vazquez A
Clin J Oncol Nurs; 2017 Apr; 21(2):154-156. PubMed ID: 28315541
[TBL] [Abstract][Full Text] [Related]
37. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.
Braschi-Amirfarzan M; Tirumani SH; Hodi FS; Nishino M
Korean J Radiol; 2017; 18(1):42-53. PubMed ID: 28096717
[TBL] [Abstract][Full Text] [Related]
38. Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review.
Abdel-Rahman O; Eltobgy M; Oweira H; Giryes A; Tekbas A; Decker M
Immunotherapy; 2017 Nov; 9(14):1175-1183. PubMed ID: 29067884
[TBL] [Abstract][Full Text] [Related]
39. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F; Sofiya L; Sykiotis GP; Lamine F; Maillard M; Fraga M; Shabafrouz K; Ribi C; Cairoli A; Guex-Crosier Y; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
Nat Rev Clin Oncol; 2019 Sep; 16(9):563-580. PubMed ID: 31092901
[TBL] [Abstract][Full Text] [Related]
40. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.
Martins F; Sykiotis GP; Maillard M; Fraga M; Ribi C; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
Lancet Oncol; 2019 Jan; 20(1):e54-e64. PubMed ID: 30614479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
